Acimtamig (AFM13) Advances in Treating CD30-Positive Tumors

Acimtamig (AFM13): A Novel Approach to Treating CD30-Positive Tumors

Acimtamig (AFM13) is an innovative immune cell engager (ICE) developed by Affimed N.V. It is designed to activate the innate immune system specifically targeting CD30-positive hematologic tumors. This bispecific tetravalent molecule enhances the body's natural ability to fight cancer by engaging natural killer (NK) cells and macrophages, effectively bridging the gap between immune cells and tumor cells for targeted destruction.

LuminICE-203 (AFM13-203) Clinical Trial

The LuminICE-203 (AFM13-203) is a Phase 2 open-label, multicenter, multi-cohort study. This trial assesses the safety and efficacy of combining acimtamig (AFM13) with Artiva Biotherapeutics' allogeneic NK cell therapy, AlloNK (AB-101). It focuses on patients with relapsed or refractory classical Hodgkin lymphoma and CD30-positive peripheral T cell lymphoma (NCT05883449). This study builds on previous results from the AFM13-104 trial, which demonstrated significant efficacy using acimtamig with cord blood-derived NK cells in treating refractory or recurrent CD30-positive lymphomas (NCT04074746).

About Affimed N.V.

Affimed N.V., listed on NASDAQ under the ticker AFMD, is a clinical-stage immuno-oncology company headquartered in Mannheim, Germany. The company is dedicated to harnessing the innate immune system's potential to combat cancer through its proprietary ROCK® platform. This platform develops customized ICE molecules targeting a wide range of hematologic and solid tumors. Affimed's pipeline includes multiple ICE candidates, either as standalone treatments or in combination therapies.

Potential Impact

The development of acimtamig (AFM13) represents a significant advancement in cancer treatment, particularly for patients with CD30-positive tumors. Its ability to engage innate immune cells offers a promising approach to improving outcomes for individuals with challenging cancer types. The ongoing clinical trials could pave the way for new therapeutic options, enhancing the quality of life and survival rates for affected patients.

Forward-Looking Statements

The information provided includes forward-looking statements regarding the potential and future developments of acimtamig (AFM13) and other product candidates by Affimed. These statements are subject to risks and uncertainties, including regulatory approvals, clinical trial results, and market conditions.

For further information, please visit Affimed's official website.